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Executive Summary 
 
 Introduction: In the post-genomic era, we are witnessing significant advances in the 
functional decipherment of the human genome sequence that have been made possible 
by new technological developments in the field of genomic medicine. This, in turn, 
has facilitated the incorporation of genetic testing services into mainstream clinical 
practice. However, in many European countries, there is very little knowledge as to 
how either the general public or medical practitioners perceive genetics and genetic 
testing services.  
 Purpose of the study and experimental approach: For this reason, we have initiated a 
pilot nationwide survey involving 1,717 individuals from the general population in 
Greece, divided according to age and residence, in order to better understand how the 
general public perceives genetic testing. At the same time, we performed a similar 
survey of 496 Greek physicians.  
 Results: Our analysis indicated that a significant number of respondents from the 
general public are aware, at least in principle, of the nature of DNA and genetic 
disorders, as well as the potential benefits of genetic testing. Moreover, a large 
proportion of the respondents were willing to undergo genetic testing even if the costs 
of analysis would not be reimbursed. Perhaps surprisingly, only a relatively small 
proportion of the general public has actually been advised to undergo genetic testing, 
either by relatives or physicians.  
 Also, a large proportion of the physicians who participated in this survey believe that 
the regulatory and legal frameworks that govern the provision of genetic testing 
services in Greece are rather weak. The vast majority of both the general public and 
physicians strongly opposes direct-access genetic testing, and would generally prefer 
referral to be from a physician rather than from a pharmacist.  
 Conclusions: Overall, these results provide the basis for an assessment of the views of 
the general public and physicians on genetics and genetic testing services in Greece. 
These surveys could be readily replicated in other populations.   
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Abstract 
Aim: Progress in deciphering the functionality of the human genome sequence in the wake 
of technological advances in the field of genomic medicine have dramatically reduced the 
overall costs of genetic analysis, thereby facilitating the incorporation of genetic testing 
services into mainstream clinical practice. Although Greek genetic testing laboratories 
offer a variety of different genetic tests, relatively little is known about how either the 
general public or medical practitioners perceive genetic testing services.  
Materials and Methods: We have therefore performed a nationwide survey of the views of 
a total of 1,717 individuals from the general public, divided in three age groups from all 
over Greece, and residing in large and smaller cities and villages, in order to acquire a 
better understanding as to how they perceive genetic testing. We also canvassed the 
opinions of 496 medical practitioners with regard to genetic testing services in a separate 
survey that addressed similar issues.  
Results: Our subsequent analysis indicated that a large proportion of the general public is 
aware of the nature of DNA, genetic disorders and the potential benefits of genetic testing, 
although this proportion declines steadily with age. Further, a large proportion of the 
interviewed sample would be willing to undergo genetic testing even if the costs of 
analysis were not covered by healthcare insurance. However, a relatively small proportion 
of the general public has actually been advised to undergo genetic testing, either by 
relatives or physicians. Most physicians believe that the regulatory and legal framework 
that governs genetic testing services in Greece is rather weak. Interestingly, the vast 
majority of the general public strongly opposes direct-access genetic testing, and most 
would prefer referral to be from a physician rather than from a pharmacist.  
Conclusions: Overall, our results provide a critical evaluation of the views of the general 
public with regard to genetics and genetic testing services in Greece and should serve as a 
model for replication in other populations.   
 
Introduction 
Personalized or genomic medicine refers to the exploitation of genomic information 
in the context of guiding medical decision-making. Examination of an individual’s genome 
sequence can, in principle at least, enable physicians to make assessments of disease risk 
and arrive at decisions regarding treatment regimens. At the same time, a number of health 
and disease states can now be identified by distinct genotypes and/or gene expression 
patterns. Hence, these molecular fingerprints can be exploited to stratify patient 
populations and to elucidate the pathogenesis of genetic disorders on a genome-wide basis 
[1,2]. We are entering an age in which individualized health care has become a reality by 
dint of taking each person’s unique genomic profile into consideration alongside their 
clinical profile [3]. Our new-found knowledge of the molecular basis of many monogenic 
and complex disorders can be exploited not only in order to optimize preventive medicine 
strategies but also to personalize conventional therapeutic interventions, either at an early 
stage in the onset of the genetic disorder or pre-symptomatically, leading to unprecedented 
opportunities for the customization of patient care [4].  
Unfortunately, among the general public, awareness may often be lacking with 
respect to genetics and its impact on society. Similarly, physicians, who are responsible for 
delivering these services to the general public, can have a relatively poor perception of 
certain issues pertaining to genomic medicine and its potential to fine-tune conventional 
medical interventions to the individual patient’s genomic profile. As a result, the landscape 
of genetic testing services is still poorly developed in many parts of Europe and the United 
States despite courageous efforts to harmonize genetic testing services (e.g. EuroGenTest 
[101]; OrphaNet [102]). Thus, at the dawn of the genomic medicine era, understanding the 
general public’s perception, as well as physicians’ opinions, with respect to the potential 
societal and individual benefits (but also the problems and pitfalls) of genetic testing, has 
become an urgent goal. For this reason, we have initiated nationwide surveys to ascertain 
patients’ and physicians’ views of the genetic testing services currently available in 
Greece, aiming to (i) understand both the wishes and needs of patients and physicians with 
regard to the genetic testing industry and (ii) identify regulatory deficiencies and gaps in 
the existing legal provision that could be rectified by appropriate legislation.  
We have previously reported our results from a nationwide survey of various 
private genetic testing providers in Greece [5]. Here, we report our findings from a survey 
of the general public’s perception and physicians’ opinion of various issues pertaining to 
genetics and its impact on society at large. Our study provides a model that can be 
replicated in other European countries with the ultimate aim of improving the public 
understanding of genetics and genetic testing, and facilitating the incorporation of genomic 
medicine into everyday clinical practice.  
 
Methods  
Research design 
A cross-sectional survey design was used for this research study which was 
conducted between June 2009 and September 2010. We formulated two independent 
questionnaires (see Supplementary information) from which the data on individual 
perceptions of genetic testing and pharmacogenomics were generated.  
In both questionnaires, non-random sampling was employed. The first 
questionnaire was personally given to 1,717 participants from the general public, that were 
selected from four major cities in Greece (Athens, Patras, Thessaloniki, Larissa), two small 
cities (fewer than 50,000 inhabitants) and two villages, including individuals with different 
occupations and ages. This questionnaire contained two main sections: the first part 
requested information such as age, gender and place of residence, whereas the second part 
contained 9 questions regarding various aspects of genetics, such as awareness of and 
personal opinion about genetics, genetic tests and the use of pharmacogenomic testing 
from health care providers. The second questionnaire was distributed to 496 physicians 
from all medical specialties that attended the national (Greek) medical conference in May 
2010. This approach was taken to ensure a truly broad coverage of physicians from all 
specialties and from all geographical regions within the country. Again, this questionnaire 
contained two sections, the first pertaining to age and gender whilst the second posed five 
questions in order to solicit the respondents’ opinions on the various potential benefits and 
pitfalls of genetic testing (see Supplementary information). We provided the necessary 
clarifications to questions posed by the survey respondents when required to do so, 
particularly in the case of the general public, in order to ensure that a valid response was 
given to each question.  
 
Measures 
The surveys provided the prospective data for this study. The dependent variables 
were derived from the questions in both surveys, scored using a binary model (0=No, 
1=Yes), whilst the independent variables comprised the demographic characteristics of 
respondents, particularly their age, gender and their place of residence. 
  
Statistical analysis 
All statistical analyses were performed using the Statistical Package for the Social 
Sciences, version 17.0 (SPSS Inc., Chicago, IL, USA). Frequency tables were obtained and 
statistical analysis was performed using the chi-square test. We also assessed the data for 
completeness and frequency distributions. Mean values, standard deviations, and 
percentages were computed to describe the distribution of independent variables. Cross-
tabulation tables (contingency tables) were created to display the relationship between two 
or more (nominal or ordinal) variables using the chi-square test. Probabilities of less than 
0.05 were considered statistically significant, when testing null hypotheses. 
 
Results 
 The overall sample sizes and characteristics of the surveyed groups are shown in 
Table 1. Every effort was made in the context of both the general public and physicians’ 
groups to be representative of the general public and medical practitioners’ populations, 
respectively, in terms of both their gender and age. In the case of the general public, only 
adult respondents were surveyed. The distribution of the general public regarding their 
place of residence broadly followed Greek demographics [103]. The questionnaires aimed 
to ascertain the opinions of the general public and physicians on the following three issues: 
(a) awareness of genetics and genetic testing, (b) access, and various other issues 
pertaining to, genetic testing, and (c) direct-access genetic testing.  
 
Awareness of genetics and genetic testing 
 We first attempted to critically evaluate the degree of education and overall 
awareness of the general public with respect to issues pertaining to genetics and genetic 
testing for both common and multifactorial genetic disorders. A significant proportion of 
the general public was found to be aware of the existence of DNA, the genetic material 
(GP-Q1), its biological role (GP-Q2), the main sources of DNA (GP-Q3) and the existence 
of public and private genetic testing laboratories (GP-Q4; Table 2); these elements were 
measured subjectively, as stated by the individuals who responded to the survey. As 
expected, there were significant differences when the respondents were subdivided 
according to their place of residence and their age. Indeed, the number of positive 
responses to these questions was inversely proportional to the age of the respondents, 
highlighting the fact that the general population is fairly uninformed about genetics. The 
same trend was also noted when the respondents were classified according to their place of 
residence, indicating reduced access of inhabitants of smaller cities and villages to 
information on genetics and genetic testing. Altogether, 84.3% of the general public 
expressed their willingness in principle to undergo genetic testing (Table 2).  
 
Access and various other issues pertaining to genetic testing 
One important parameter in personalized medicine is access to genetic testing for 
both common and multifactorial genetic disorders. Our surveys of both the general public 
and physicians were designed to address this aspect. From the physicians’ questionnaire, 
we found that 74.5% would themselves be willing, at least in principle, to undergo genetic 
testing (Fig. 1A). However, a significantly lower percentage (48.5%) had encouraged their 
patients to undergo genetic testing (Fig. 1B). More specifically, 42.1% had encouraged 
their patients to undertake a genetic test for a monogenic or multifactorial disorder, 30% a 
cytogenetic test and 16.1% a pharmacogenomic test (Fig. 1D). In the context of our own 
approach, molecular genetic testing was taken to refer both to monogenic and complex 
disease, the latter resulting from the interaction of genetic predisposition, negative lifestyle 
or other environmental factors. Despite the fact that both monogenic and complex disease 
involve the same sort of genetic analysis in the laboratory, the context and the 
interpretation of testing is very different in the two cases. These results are consistent with 
the nature of the genetic tests provided by private genetic testing laboratories in Greece, as 
indicated by our previous study [5]. Surprisingly, the general public indicated that only 
9.5% had been encouraged to undertake a genetic test by their physicians, friends, relatives 
or a genetic laboratory representative (Fig. 1C). However, this proportion varied 
significantly when those who responded to the query were classified according to their 
place of residence, age or gender (Fig. 1E). 
 We then sought the general public’s view as to their willingness to undertake a 
genetic test even if the costs would not be reimbursed by their insurance companies. It 
emerged that 54.8% of the general public would be willing to undertake a genetic test even 
if the costs would not be reimbursed (Fig. 2B). Again the proportion of those willing to 
take a genetic test for a monogenic or multifactorial disorder was significantly larger 
(94.1%) than those willing to take a pharmacogenomic test, in a situation where the 
analysis costs would not be reimbursed (Fig. 2C). In concert with this finding, 77.3% of 
the physicians who responded to our questionnaire were of the opinion that the costs of 
genetic testing services should be reimbursed by insurance companies (Fig. 2A). However, 
it is noteworthy that a mere 11.9% of physicians believe that there is currently a 
satisfactory legal framework in Greece to cover aspects of genetic testing (Fig. 3) such as 
data privacy, written informed consent, genetic testing laboratory accreditation, regulation 
of genetic testing costs to avoid overpricing, and so on. This finding is again consistent 
with our previous finding indicating considerable variation in the accreditation of the 
various private genetic laboratories in Greece, the type of accreditation certificate, genetic 
testing pricing and the absence, in most cases, of a proper procedure to communicate 
results to the patients [5]. 
 
Direct-access genetic testing 
Another very important aspect of genetic testing, with serious attendant ethical and 
(often) legal implications is direct-access testing, also known as direct-to-consumer genetic 
testing [6]. From our previous analysis, it is clear that at least one genetic service 
laboratory in Greece offers direct-access genetic testing as part of its public outreach 
strategy. In addition, buccal swab sampling kits for genetic testing are sold over the 
counter in at least one chain of pharmacies in Greece, while other pharmacies provide the 
same sampling kit upon request. We therefore sought the opinions of both the general 
public and physicians about direct-access genetic testing. Interestingly, only a very small 
proportion of the physicians (12.7%; Fig. 4A) were in favour of direct-access genetic 
testing, although this proportion was slightly higher among the general public (17.9%, 
p=0.001; Fig. 4C). Of those individuals from the general public who were against direct-
access genetic testing (82.1%), the vast majority wanted a physician to direct them to 
genetic testing services and then to explain the test results (96.6%; Fig. 4D), whereas only 
20.4% wanted a pharmacist to refer them to a genetic testing laboratory. These proportions 
varied significantly when the responders were classified according to their place of 
residence (Fig. 5), underlining the fact that only 7.7% of the responders who were living in 
a village favoured direct-access genetic testing services (p=0.036). Similarly, according to 
the physicians who were against direct-access genetic testing, the vast majority (89.7%) 
believed that a physician should refer patients and/or interested individuals to a genetic 
testing laboratory whilst only 5% believed that a pharmacist should be allowed to perform 
this task (Fig. 4B).  
 
Discussion  
The steady increase in the availability of genetic tests is a direct result of the 
exponential rate of discoveries in the field of human genomics, the technology now 
available for genome analysis [7], and our burgeoning knowledge of genotype-phenotype 
correlations. According to one estimate, more than 700.000 genetic tests are performed in 
Europe annually in both public and private genetic laboratories [8], and this is expected to 
increase in the years to come. In contrast to the United States, in Europe there are 
significant differences between individual countries, even between European Union 
member states, regarding genetic testing services. In other words, in some countries, there 
are established regulatory frameworks and provisions for genetic testing services, whereas 
in others the area is still not properly regulated (for an overview of the existing regulatory 
frameworks on genetic testing services, see the European Society of Human Genetics 
website [104]). Although there has been some attempt to harmonize genetic testing 
practices across Europe, an in-depth analysis, based upon comprehensive surveys of the 
current situation in European countries is still lacking. Presently, only a handful of studies 
have been performed in European populations to assess the attitude of the general public 
towards genetics and genetic testing services, namely in Finland [9], Germany [10] and 
Russia [11].  
The present study complements our previous work on the private genetic testing 
environment in Greece [5], by attempting to explore how both the general public and 
medical practitioners perceive genetics and genetic testing services in the country. It was 
designed to explore how the Greek general public and their attending physicians perceive 
genetics and genetic testing, what their opinions are with respect to the regulatory and legal 
frameworks that oversee these services and what they think about the concept of direct-
access genetic testing which has recently gained significant popularity. These surveys are 
not only among the very first of their kind performed in Europe, namely Finland and 
Germany, but also paid special attention (for the first time in Europe) to attitudes to 
pharmacogenomic testing since this emerging discipline is anticipated to have a central 
role in translational medicine in the future.  
Our surveys included a large number of participants from the general public and 
physicians. We opted to carry out personal interviews rather than acquire information 
through electronic surveys since, from our own experience, the latter approach would not 
have yielded a satisfactory number of responses, particularly from older people and those 
living in smaller cities and villages who are likely to be less computer literate. Moreover, it 
would have probably introduced bias since those people who are most computer literate are 
also likely to be the most informed about genetic testing for a variety of reasons. 
Participants from the general public were therefore approached in several public places, 
such as pharmacies, supermarkets, cafés and restaurants, while physicians were selected 
while attending a major national medical conference in Athens. We fully appreciate that 
few of our questions required a simple “yes/no” answer, a study design which may not 
always provide the most useful insights when seeking to identify whether the public is 
aware of some specific fact or issue. On the other hand, we wished to avoid eliciting 
stereotypical responses and kept the questionnaire simple and easy to answer in order to 
encourage maximum participation on the part of our respondents, particularly the main 
target groups.  
 
Overall perception of genetics and genetic testing 
Our first attempt was to critically evaluate the degree of education and overall 
awareness of the general public with respect to issues pertaining to genetics and genetic 
testing. As indicated in Table 2, the majority of the general public was aware of the nature 
and role of the genetic material, as well as the various different sources from which an 
individual’s DNA can be obtained. They were also well aware of the existence of both 
public and private genetic testing laboratories while 84.3% of the general public expressed 
their willingness to undergo genetic testing (Table 2). This proportion was markedly 
similar to that observed for a similar sized urban Russian population, where 85% of 2000 
respondents answered positively to a question about their own willingness to undergo 
predictive genetic testing for preventable health conditions [11]. However, only a small 
proportion of people have actually been encouraged to undergo genetic testing by a 
physician, a relative or even a laboratory representative (Figs. 1C, E). Intriguingly, this 
proportion is somewhat lower than the professed willingness of the physicians to direct 
their patients to genetic testing services, if deemed necessary (Fig. 1B). This finding can be 
explained by the fact that although physicians are willing in principle to recommend 
genetic testing to their patients, in practice they often fail to do so. One possible 
explanation would be a lack of understanding and/or poor education with respect to the 
potential benefits of genetic testing of monogenic and complex disorders, classical or 
molecular cytogenetics, and pharmacogenomics. This concurs with a previous study which 
indicated that only 5% of prescribers of azathioprine had requested DNA testing for 
variants in the TPMT gene to determine the ability of their patients to respond to the 
treatment [12]. Furthermore, significant differences were observed among the responses of 
the general public according to their places of residence, their age and, in certain cases, 
their gender (Table 2), which can again be explained by a lack of awareness of genetics 
and issues pertaining to genetic testing. These data are comparable to a similar sized study 
conducted in Russia, indicating that gender and age significantly influenced responses of 
the 2000 respondents that participated in this survey [11]. Our results also indicated that 
genetic tests for a monogenic or multifactorial disorder are strongly preferred over 
cytogenetic and pharmacogenomics tests (Fig. 1D), as indicated by the physicians’ 
responses; these findings are concordant with our companion study of private genetic 
testing laboratories in Greece [5]. Similar results have also been reported from a 
comparable study in the UK, albeit involving a significantly smaller number of individuals 
[13]. 
The reimbursement of genetic testing costs by insurance companies is another 
important parameter of genetic testing to consider. The lack of any reimbursement could 
discourage interested parties from undergoing genetic testing, especially when costs are 
rather high or the patients are from a low-income bracket. A significant proportion (54.8%) 
of the general public expressed their willingness to take a genetic test even if the costs 
would not be reimbursed (Fig. 2B), and again a preference for genetic testing for a 
monogenic or multifactorial disorder over pharmacogenomic testing was evident (Fig. 2C). 
Of course, this proportion is critically dependent on the health benefits, as these are 
perceived by the patient, and hence the latter percentage is likely to be smaller in relation 
to those tests that do not provide such information, e.g. pharmacogenomic tests predicting 
drug toxicity versus efficacy, respectively. These findings contrast with those from a recent 
survey in Canada which indicated that very few respondents were willing to pay for 
genetic testing to acquire information about genetic factors related to clinical disorders and 
62% indicated that the public healthcare system should reimburse these tests [14]. It should 
be noted that the latter survey performed in Canada distinguished genetic tests with the 
type of information to be gained from it (such as genetic factors related to manageable 
conditions or serious, unpreventable disease, etc) and specified how much one is willing to 
pay (in cash brackets), and as such is not directly comparable to our present study. 
Importantly, over 75% of the physicians questioned thought that the costs of 
genetic testing services should be reimbursed by insurance companies (Fig. 2A). Our 
questionnaire that was addressed to physicians did not distinguish between genetic testing 
for inherited disorders and pharmacogenomic testing; it would therefore be interesting to 
see if physicians differ from the general public in terms of their thinking on this issue. 
These findings should constitute a major driving force behind efforts to establish the 
necessary regulatory framework so that genetic testing costs can be reimbursed as of right. 
In their responses, the physicians emphasized the lack of a satisfactory legal framework to 
cover genetic testing (Fig. 3), such as the accreditation of genetic testing laboratories, data 
privacy, written informed consent and the regulation of genetic testing costs. In Greece, 
genetic testing services are mainly regulated through the legal framework that applies to 
the Greek national health care system as a whole and there are no dedicated laws 
specifically intended to cover genetic testing services. The regulations on patient rights are 
readily applicable as rights of genetic services users. The authority of the Greek Bioethics 
Committee is restricted to provide some important recommendations that complement the 
existing legislation. Our companion study [5] demonstrated that there is considerable 
variability in terms of (i) the accreditation of the various private genetic laboratories in 
Greece, (ii) the nature of their accreditation certificate, (iii) the cost of genetic testing and 
(iv) the proper means (or not, in most cases!) to communicate test results to the patients. 
There is a clear gap in current Greek legislation regarding direct-access genetic testing (see 
also below). Indeed, the Hellenic Society of Medical Geneticists [105] (content in Greek) 
and the Hellenic Bioscientists Association [106] (content in Greek) have both published 
warnings about direct-access testing services being offered by Greek private genetic 
laboratories (using call centers or advertising these tests over the Internet), stressing that 
these are highly specialized tests whose potential benefits and results cannot possibly be 
communicated by these means and by people who have not received the appropriate 
training.  
 
Direct-access genetic testing and society 
Direct-access genetic testing represents a very controversial issue with serious 
ethical and societal implications [15]. More than 1,000 genome variants are associated with 
susceptibility to genetic disorders and as a result, since 2007, an increasing number of 
genetic tests for common disorders and ‘predictive markers’ are available, most of which 
lack sufficient evidence of clinical validity, any proper meta-analysis of the marker(s) in 
question, and hence their utility in a clinical setting is doubtful [16]. These tests can be 
purchased via the Internet or over the counter in pharmacies in the United States and 
certain European countries, without the need for a medical specialist or biomedical 
scientist as intermediary. The results of these tests may therefore confuse the purchasers, 
and may falsely cause concern or even distress, or conversely provide false reassurance, 
while the lack of proper communication of the test results by a medical specialist deprives 
people of an adequate explanation for the potential consequences of the test result or of 
possible courses of remedial action in relation to their health. In other words, taking such 
tests may simply be a waste of money, thereby negatively impacting upon the public’s 
opinion and diminishing their trust in genetic testing as used for bona fide medical 
purposes [17]. 
Our companion survey to private genetic laboratories indicated that at least one 
genetic laboratory in Greece offers direct-access genetic testing services [5], which had 
unfortunately not responded to our survey. Since direct-access genetic testing is a rather 
controversial issue and very few studies have previously been performed to canvass the 
general public’s and physicians’ opinions, we decided to include this topic in our surveys. 
Our results indicate that very few physicians (12.7%) favour direct-access testing (Fig. 
4A), although a slightly larger proportion of the general public hold the same view (17.9%; 
Fig. 4C). In the latter case, this percentage was significantly higher compared to that 
obtained from a study performed in the UK [18], indicating that only 5% of the 
respondents would be willing to undertake such a test, even if the price were less than 250 
GBP. In the same study, a surprising 50% responded positively to the hypothetical 
question as to whether they would be willing to undertake such a test even if it were 
offered free of charge. These data concur with similar results from the United States 
[19,20], indicating that individuals undergoing direct-access genetic testing have 
significant concerns about the entire process. Such information was not previously 
available in European populations [21], which was another important outcome from our 
surveys. Thus, the majority of both physicians and the general public are largely against 
direct-access genetic testing. This of course raises serious concerns with respect to the 
marketing channels that these laboratories employ to attract new customers. For example, 
advertising these tests through the Internet is the norm, whereas other marketing channels 
include cold-calls, ads in newspapers, or even information days at various venues (schools, 
municipal health centers, etc) from scientists collaborating with these laboratories. 
Preliminary data from our meta-analysis of several genes and DNA variants included in the 
tests offered indicate that, in the case of at least two genes and their accompanying 
variants, there is insufficient scientific evidence to include data pertaining to these 
genes/variants in the calculation of the overall risk (in preparation). This of course poses 
some serious concerns regarding the scientific accuracy of the results obtained.  
Generally, those physicians and members of the general public who intimated that 
they were against direct-access genetic testing also indicated that they preferred a 
physician rather than a pharmacist to refer the interested parties to a genetic laboratory. 
Generally, physicians and pharmacists are the key interlocutors for the general public and 
this indeed was our reason for including them in the survey. In particular, 96.6% of the 
general public wished a physician to refer them to a genetic laboratory and to explain the 
test results to them, with a significantly smaller percentage (20.4%) being content to go 
through a pharmacist. These percentages varied significantly when the responders were 
classified according to their place of residence (Fig. 5), emphasizing the fact that only 
7.7% of the responders who were living in a village favoured direct-access genetic testing 
services. Similarly, with respect to the physicians who were against direct-access genetic 
testing, the vast majority (89.7%) believed that only a physician should refer patients and 
interested individuals to a genetic testing laboratory whereas only 5% believed that it was 
appropriate for a pharmacist to undertake this task (Fig. 4B). These findings should be 
considered alongside the results of our companion study [5], which established that one 
Greek pharmacy group promotes genetic tests and sells DNA sampling kits to the public 
over the counter whereas other pharmacies are generally willing to order these sampling 
kits upon request. We have made enquiries with several pharmacies about the demand for 
these kits but it would appear that the demand is very low.  
 
Conclusions  
We provide here results from two nationwide surveys to assess the general public’s 
awareness of, and physicians’ opinion on, genetic testing services in Greece. Participants 
in our surveys were relatively well informed about genetics but, at the same time, more 
skeptical towards certain aspects of genetic testing, particularly direct-access genetic 
testing. In other words, it would appear that a better-informed general public harbours 
more critical views and is not necessarily more supportive of new genetics research and 
discoveries. Our results provide significant new insights into the potential benefits and 
pitfalls of genetic testing in Greece. Our future goal is to expand this study in order to 
acquire further insight into both public and physician’s attitudes towards genetic testing so 
that legal issues and regulatory weaknesses may be addressed with the aim of ensuring that 
the field will come to be adequately and appropriately regulated. To this end, it is hoped 
that the existing gap between the overall provision of genetic testing in Europe and the US 
will somehow be bridged. Our study not only provides the basis for a critical appraisal of 
the genetic testing environment in Greece but also stands as a model for replication in 
other countries to assess the landscape of genetic testing services.   
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Figure legends 
Figure 1 
Appraisal of access of physicians and the general public to genetic testing services. 
Outcome of the survey of physicians’ willingness to personally undertake a genetic test (P-
Q3; A) and to direct their patients to genetic testing services (P-Q4; B), with a particular 
focus on genetic (P-Q4a), cytogenetic (P-Q4b) and pharmacogenomic testing (P-Q4c; D). 
Outcome of the general public’s feedback with respect to whether their physicians have 
recommended them to take a genetic test (GP-Q5; C) and detailed depiction of their 
positive replies in the various subgroups, regarding their place of residence, age and gender 
(E). *: p<0.5, **: p<0.01. Positive answers are depicted in green, negative answers in red.  
 
Figure 2 
Opinions of the physicians and the general public with regard to genetic testing and 
reimbursement of the corresponding costs. Physicians’ opinion of the reimbursement of 
genetic testing costs (P-Q1; A), willingness of the general public to undergo genetic testing 
when analysis costs are not reimbursed by insurance companies (GP-Q8; B) and 
differences with respect to genetic and pharmacogenomic tests (GP-Q8a and GP-Q8b; C). 
Positive answers are depicted in green, negative answers in red.  
 
Figure 3 
Physicians’ opinion with regard to the existence of the necessary legal framework covering 
genetic testing in Greece (P-Q2). Positive answers are depicted in green, negative answers 
in red.  
 Figure 4 
Opinions regarding direct-access genetic testing in Greece. Physicians’ overall views 
on the concept of direct-access genetic testing (P-Q5, P-Q5a and P-Q5b; A, B) and the 
corresponding view of the general public (GP-Q9, GP-Q9a and GP-Q9b; C, D). Positive 
answers are depicted in green, negative answers in red.  
 
Figure 5 
Differences in the views expressed by the general public with respect to direct-access 
genetic testing, according to their place of residence (see also text for details).  
Table 1 
Survey sample composition and demographic elements. a: Our questionnaires included 
adult respondents with a minimum age of 18-years. b: Fewer than 50,000 inhabitants. 
 
General Public (n) 1,717 Physicians (n) 496 
 %  % 
Age (years) Age (years) 
<35 a 32.6 <35 a 32.6 
35-60 49.5 35-60 54.4 
>60 17.9 >60 11.9 
Gender Gender 
Male 46.9 Male 48.3 
Female 53.1 Female 51.7 
Place of residence  
City 63   
Smaller City b 33.2   
Village 2.8   
 
 
Table 2 
Critical evaluation of the awareness of the general public on DNA and genetic testing services. Statistically significant values are shown in 
boldface. 
  GP-Q1 p-value GP-Q2 p-value GP-Q3 p-value GP-Q4 p-value GP-Q6 p-value GP-Q7 p-value 
Place of 
residence 
City 93.7 0.000 80.8 0.000 87.6 0.000 72.3 0.000 85 0.535 77.4 0.375 
Small city 90 0.000 77.5 0.000 82.2 0.000 65.8 0.000 82.9 0.535 74.7 0.375 
Village 61.5 0.000 16.9 0.000 0 0.000 0 0.000 83.1 0.535 80 0.375 
Age 
(years) 
<35 94.6 0.000 85.5 0.000 92.1 0.000 81.7 0.000 87.1 0.066 74.4 0.133 
35-60 90.7 0.000 82.1 0.000 78.2 0.000 65 0.000 83.3 0.066 78.7 0.133 
>60 86.6 0.000 60 0.000 66.2 0.000 48.1 0.000 81.8 0.066 75 0.133 
Sex 
Male 88.9 0.001 74.8 0.017 80.3 0.027 63.9 0.004 81.6 0.004 74.6 0.068 
Female 93.3 0.001 79.6 0.017 84.4 0.027 70.5 0.004 86.6 0.004 78.4 0.068 
Overall Positive 91.3 
 77.3  82.5  67.5  84.3  76.6  
Abbreviations: GP-Q1-4,6,7: General public-Question1-4,6,7 
